Streetbeat News

Products Services

APLS

Apellis Pharmaceuticals and Sobi announced positive Phase 3 VALIANT study results for Pegcetacoplan in treating rare kidney diseases, achieving a 68% reduction in proteinuria. The results were consistent across all subgroups, and data submission is planned for the US and EU. Apellis will host a conference call at 8:00 AM ET.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 11:20 am

OPTN

Optinose has revised its FY24 net revenue guidance for XHANCE, narrowing the range from $85M-$95M to $85M-$90M. Additionally, the company has increased its expected average net revenue per prescription to at least $250.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 11:17 am

AMZN

VERI

Veritone has signed a three-year strategic collaboration agreement with Amazon Web Services (AWS) to drive AI and cloud innovation across various sectors including media, entertainment, sports, talent acquisition, and public sectors.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 11:17 am

ALDX

Aldeyra Therapeutics announced that its Phase 3 trial for Reproxalap Ophthalmic Solution in treating dry eye disease achieved its primary endpoint, showing statistically superior results for ocular discomfort. The company plans to resubmit its NDA in 2024.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 11:15 am

ORGN

Origin Materials and Reed City Group have announced a partnership to mass produce PET caps and closures in North America. The first production line is set to launch in Q4 2024, aiming to enhance recycling circularity and packaging efficiency.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 11:13 am

ZTEK

Zentek Ltd. (NASDAQ:ZTEK) announced the start of a three-year, $441,000 project in collaboration with University of Toronto professors, funded by an NSERC Mission Alliance Grant. The project focuses on sustainable materials and bioproducts.

Portfolio Pulse from charles@benzinga.com

August 08, 2024 | 11:10 am

IRWD

Ironwood Pharmaceuticals has revised its FY 2024 financial guidance due to continued pricing pressure on Linzess, driven by higher-than-expected Medicaid utilization trends. The company now expects sales of $350M-$375M, down from the prior range of $405M-$425M and below the consensus of $410.05M.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 11:08 am

MSFT

PLTR

Palantir shares are trading higher following the announcement of a partnership with Microsoft to enhance analytics and AI services for classified networks.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 11:02 am

MSFT

PLTR

Palantir and Microsoft are advancing their partnership to offer advanced cloud, AI, and analytics capabilities to the U.S. defense and intelligence community. This includes integrating Microsoft's Azure OpenAI Service within Palantir's AI platform.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 10:59 am

F

Ford Motor Co (NYSE:F) has introduced higher-end variants of the 2025 Ford Maverick truck after witnessing an 80% increase in sales for the model in 2024 through July. The new variants, Tremor and Lobo, are priced at $39,795 and $40,495 respectively, with orders starting on August 1 and deliveries set for early 2025.

Portfolio Pulse from Anan Ashraf

August 08, 2024 | 10:56 am